Skip to main content
. Author manuscript; available in PMC: 2011 Feb 1.
Published in final edited form as: Clin Cancer Res. 2010 Jul 2;16(16):4217–4225. doi: 10.1158/1078-0432.CCR-10-0777

Fig. 2. The reduced biological activity of ABT-263 is not due to a reduced potency or plasma membrane permeability.

Fig. 2

A, F-dextran loaded liposomes were incubated with BAX, N/C-BID and BCL-XL and the indicated concentrations of ABT-737 or ABT-263 (0.04, 0.2, 1 or 5 μM) for 2.5 h at room temperature. Both ABT-737 and ABT-263 reversed BCL-XL mediated inhibition of BAX and N/C-BID liposome permeabilization. B, Purified CLL cells were treated with 0.05% digitonin to permeabilize the plasma membrane and the cells were washed and pelleted by centrifugation at 13000 rpm. The permeabilized cells were incubated with different concentrations of ABT-737 and ABT-263 for 1 h at 37°C. The release of cytochrome c (Cyt c) from the cell pellet into the supernatant (SN) was assessed after centrifugation by western blotting.